In-depth Analysis of the COVID-19 Impact on Global BRIC Diagnostic Imaging Equipment Market

The report “BRIC Diagnostic Imaging Equipment Market by Modality ((X-Ray Imaging (Digital, Analog), MRI (High & Low Field), CT (Conventional, CBCT), Nuclear Imaging (SPECT, Hybrid PET)), End User (Hospitals, Imaging Centers) – Global Forecast to 2024″, is Diagnostic Imaging Equipment Market projected to reach USD 8.3 billion by 2024 from USD 5.3 billion in 2019, at a CAGR of 9.2% from 2019 to 2024.

The Rapidly growing geriatric population coupled with the subsequent increase in the prevalence of associated diseases and increasing demand for early disease diagnosis are some of the key factors fueling market growth. Moreover, technological advancements in diagnostic imaging modalities and increasing investments, funds, and grants by public-private organizations are anticipated to further drive the growth of the diagnostic imaging market in BRIC countries.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=242

Hospitals were the largest end-user segment in the market in 2018;

On the basis of end users, the hospitals segment commanded the largest share of the BRIC diagnostic imaging equipment market in 2018. The large share of this segment can be attributed to the rising number of diagnostic imaging procedures performed in hospitals, growing inclination toward the automation and digitization of radiology patient workflow, and increasing adoption of minimally invasive procedures.

Geographical View in-detailed:

On the basis of countries, segmented into Brazil, Russia, India, and China. China accounted for the largest share of the BRIC diagnostic imaging equipment market in 2018, followed by India. China has a dynamic and fast-growing healthcare industry with significant government emphasis on the modernization and expansion of the rural healthcare infrastructure. Moreover, rising geriatric population and associated diseases, easy accessibility to diagnostic imaging modalities, and rising adoption of advanced modalities are the key factors fueling the growth of the Chinese market.

Global Key Leaders:

The major players in the market include GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), Canon Medical Systems Corporation (Japan), Carestream Health, Inc. (US), Hologic, Inc. (US), Hitachi, Ltd. (Japan), Neusoft Corporation (China), Allengers (India), CURA Healthcare (India), NP JSC Amico (Russia), SONTU Medical Imaging Equipment Co., Ltd. (China), FUJIFILM Holdings Corporation (Japan), and United Imaging Healthcare Co, Ltd. (China), among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=242

Koninklijke Philips N.V. (Netherlands) held the major share of the BRIC diagnostic imaging equipment market in 2018. As part of its strategy, Philips focuses on product launches and expansions to increase its market share in this highly competitive market. China offers significant opportunities for Philips due to its large patient pool and developing healthcare infrastructure. In order to deliver technologically advanced solutions at economical prices, the company established an AI lab in Shanghai, China. The company has also entered into partnerships & collaborations with various companies and organizations in the country to enhance its market share.

Siemens Healthineers (Germany) held the second position in the BRIC diagnostic imaging equipment market in 2018. The company has a significant presence in BRIC nations and offers a number of modalities in the diagnostic imaging market. With a robust product portfolio, Siemens Healthineers holds a strong position in the diagnostic imaging market. To maintain its competitive position, the company focuses on new product launches and expansions as key organic growth strategies. In 2018, the company introduced the Mammomat Revelation Mammography System and NX Series Ultrasound machines in India. These developments have helped the company to expand its customer base and strengthen its geographical footprint across the globe. Siemens is considered as one of the key players in the global market due to its vast product portfolio and strong distribution channels. Moreover, the company invested around USD 6.6 billion, USD 5.7 billion, and USD 5.3 billion in R&D during 2018, 2017, and 2016, respectively.

Thyroid Function Test Market Size, Share, Growth, Trend and Forecast 2022

The report “Thyroid Function Test Market by Type (TSH Tests, T4 Tests, T3 Tests), End User (Hospitals, Diagnostic Laboratories, Research Laboratories & Institutes), and Region (North America, Europe, APAC, LATAM, and MEA) – Global Forecast”, is expected to reach USD 1.68 Billion, at a CAGR of 5.9%.

The Growth of the market can primarily be attributed to the increasing incidence of thyroid disorders, increasing awareness about thyroid disorders, increasing prevalence of lifestyle diseases, rising geriatric population, and increasing consumption of alcohol & tobacco. Growth opportunities in emerging Asia Pacific countries to provide lucrative growth opportunities for players in the thyroid function tests market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=85085049

Objectives of the Study:

• To define, describe, segment, and forecast the global market by type, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
• To analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To profile the key players and comprehensively analyze their product portfolios, market shares, and core competencies in the global thyroid function tests market

The TSH tests segment is expected to account for the largest share of the market.

On the basis of type, segmented into TSH tests, T4 tests, T3 tests, and other tests. In 2017, the TSH tests segment is estimated to account for the largest share of the thyroid function tests market. The large share rate of this segment can be attributed to the fact that TSH tests are initially prescribed by physicians to majority of patients (for the assessment of thyroid gland functioning) showing symptoms of thyroid disorders.

Geographical View in-detailed:

The North American market is expected to account for the largest share of the global thyroid function test market due to the presence of an advanced healthcare infrastructure in North American countries such as the US and Canada. However, the Asia Pacific market is expected to grow at the highest CAGR in the forecast period. This growth can be attributed to factors such as the presence of a large target patient population, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India.

Global Key Leaders:

The prominent players in the global thyroid function test market include Thermo Fisher (US), Abbott (US), Roche (Switzerland), DiaSorin (Italy), Danaher (US), Kronus (US), Merck (Germany), Cortez Diagnostics (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China).

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=85085049

COVID-19 Impact on Vaccines and Drugs Market - Global Key Players, Trends, Industry Size & Forecast

The report “COVID-19 Impact on Vaccines and Drugs Market – Global Forecast to 2025″ the COVID-19 impact on the global vaccines market size is estimated at USD 2,273 million in 2022 and projected to reach USD 1,401 million by 2025, resulting in a CAGR of -14.9%. On the other hand, the COVID-19 impact on the global drugs market size is anticipated at 165 million in 2020 and estimated to reach USD 2 million by 2025, at a CAGR of -57.8%.

The growth of the COVID vaccines market is attributed majorly to the increasing number of people infected with coronavirus and growing funding for vaccine development. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, the emergence of alternate therapies, such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=112248051

Funding from global governments and foundations is promoting the growth of the market;

Incentives are needed to engage manufacturers for the large-scale capacity to guarantee sufficient production of SARS-CoV-2 vaccines. In line with this, various global organizations have come forward to expedite the process, such as Gavi, CEPI, and WHO. However, considering the pandemic scenario of COVID-19, much stronger initiatives are required.

In April 2020, the Bill and Melinda Gates Foundation announced plans to help fund factories for seven promising vaccines, even before seeing conclusive data. The foundation aims to help scale up manufacturing during testing, rather than after the vaccines have passed the trials.

Besides the most promising Moderna program, several other big pharma companies are involved in COVID-19 vaccine work. Johnson & Johnson has pledged a manufacturing scale-up to 1 billion doses for its federally partnered program. Meanwhile, Sanofi has two partnerships underway—one with the federal government and another with Translate Bio.

Some of the major players in the COVID-19 vaccines market include Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=112248051

Some of the key players are collaborating to expedite the vaccines and drug development. For instance, In February 2020, Janssen announced that it would work collaboratively with laboratories to screen antiviral therapies. Janssen already donated several doses of PREZCOBIX (for research use) to the Shanghai Public Health Clinical Center, Zhongnan Hospital of the Wuhan University, and the Chinese Center for Disease Control and Prevention. Big players in vaccines have also entered the race of launching vaccines targeting COVID-19, such as GSK and Sanofi. Sanofi and GSK are coming together to work on a Covid-19 vaccine, which, if it passes clinical trials, will become available in the next 12- 18 months’ timeline.

Clinical Risk Grouping Solutions Market - Growth Factors Analysis, Share and Forecast

The report “Clinical Risk Grouping Solutions Market by Product (Scorecard & Visualization Tools, Dashboard Analytics, Risk Reporting), Deployment (Private Cloud, Public Cloud, Hybrid Cloud), End-User and Region – Global Forecast to 2024″, projected to reach USD 829 million by 2024 from USD 427 million in 2019, growing at a CAGR of 14.2%.

The Factors such as increasing focus on risk management solutions in the healthcare industry and rising implementation of big data solutions are driving the market for clinical risk grouping solutions. Increasing instances of physician burnout due to clinical documentation and a shift towards software based on AI and machine learning also present significant growth opportunities for market players.

Clinical Risk Grouping Solutions Market Share Estimation;

The market shares for clinical risk grouping solutions companies was arrived at after detailed assessment of their revenues from the clinical risk grouping solutions business by secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases revenue share was arrived at after detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews.

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=72780829

Based on the product, segmented into scorecard & visualization tools, dashboard analytics, and risk reporting solutions. The scorecard & visualization tools segment accounted for the largest share of the clinical risk grouping solutions market in 2018. The large share of this segment can be attributed to the high usage of risk attributing and risk scoring usage in clinical risk grouping solutions.

Geographical View in-detailed:

The clinical risk grouping software market in North America is driven by the growing focus on quality care, increasing focus on population health management, and cost containment in the healthcare industry. Also, a highly suitable healthcare IT infrastructure and rising adoption of clinical risk grouping solutions by healthcare payers in the region are supporting the growth of clinical risk grouping solutions in this region.

Global Key Leaders:

3M Corporation (US) and Optum, Inc. (US) dominated the global clinical risk grouping solutions market in 2018. The prominent players in the global market are Cerner Corporation (US), Conduent Inc. (US), Nuance Communications (US), Health Catalyst (US), HBI Solutions (US), Johns Hopkins University (US), Lightbeam Health Solutions (US), Dynamic Healthcare Systems (US), 4S Information Systems (US), Evolent Health (US), and PeraHealth (US).

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72780829

3M Corporation (US) is a diversified company with a wide range of product offerings across different industries. The company has more than 30 years of experience in developing solutions for classification, grouping, and reimbursement calculation systems for inpatient, outpatient, and professional settings. This platform of innovative services, along with a comprehensive product portfolio for clinical risk grouping makes it a leading market player in the clinical risk grouping solutions market. 3M relies on product innovation internally. For instance, the company’s R&D expenditure in 2018 was USD 1.82 billion, which accounts for 6% of its total revenue.

Optum, Inc. (US) provides a variety of healthcare IT solutions such as EHR/EMR solutions, mHealth solutions & services, ePrescribing, healthcare asset management solutions for pharmacies, revenue cycle management solutions and facilitates the complete lifecycle of its patient access, clinical documentation process, claims, eliminating multiple systems, and inefficient manual mid-revenue cycle processes. It also offers healthcare IT solutions and services to help care providers and health care payers efficiently improve their clinical performance, quality of care, and establish consumer engagement.

Cell Signaling Market Size, Share on Global Analysis Report

The report “Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) – Global Forecast “, is expected to reach $3.51 billion, at a CAGR of 6.8%

The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.

Cell signaling is used to study signaling pathways of cells in drug discovery and therapeutic development, to distinguish drug resistance patterns in cancerous cells. It also identifies the major signaling pathways impacted by specific drug treatments. Cell signaling pathways—also called signal transduction pathways—act as connecting links between environmental stimuli and the corresponding cellular response. These signaling pathways mainly consist of proteins that can interact, move to specific locations, or be modified.

Don’t miss out on business opportunities in “Cell Signaling Market”. Speak to Our Analyst and gain crucial industry insights that will help your business growth:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=80206120

Availability of funding cell based research is key driver for the global cell signalling market;

Governments of various countries are promoting and supporting cell-based research activities such as cell signalling, single-cell analysis, and stem cell research. A large portion of the funding from governments is provided to academic research societies to promote cell-based research, which helps in the evaluation of diagnostic and therapeutic applications of various types of cells in the management of chronic and infectious diseases. By driving research into the application and end-user industries for cell analysis, the availability of support plays a significant role in aiding market growth.

Market Segmentation in Detailed:

Based on product, segmented into consumables and instruments. The cell signaling consumables segment is estimated to account for the largest share of the cell signaling market. The increasing number of cell signaling research activities and rising incidence of chronic diseases are some of the major factors contributing to the segments large market share.

On the basis of technology, segmented into enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), microscopy, flow cytometry, western blotting, mass spectrometry, and other technologies (immunofluorescence and immunoprecipitation). The microscopy segment is estimated to account for the largest share.

Geographical View in-detailed:

The Cell Signaling Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to account for the largest share of the market. Growth in this regional segment is driven by the growth in geriatric population, rising incidence of chronic diseases, and improved life science research infrastructure in the region.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80206120

Global Key Leaders:

The key players in the cell signaling market include Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Becton, Dickinson and Company (U.S.), Beckman Coulter, Inc. (U.S.) (a subsidiary of Danaher Corporation), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer Inc. (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Abcam plc (U.K.), Miltenyi Biotec (Germany), Full Moon BioSystems, Inc. (U.S.)

Viral Inactivation Market Size, Share, Outlook, Industry Analysis Report 2021

The report “Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) – Global Forecast”, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global viral inactivation market along with the estimates and forecasts of the revenue and market share analysis.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry. Increasing number of new drug launches, rise in chronic disease burden, and increasing government support for the pharmaceutical and biotechnology industries will also aid the growth of this market.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121427017

Viral Inactivation Market Segmentation in Detailed:

By method, the market is divided into solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light. Of these, the solvent detergent method segment accounted for the largest share of the global viral inactivation market.

By application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Of these the vaccines and therapeutics application hold the highest share.

By end user, segmented into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121427017

Geographical View in-detailed:

The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.

Global Key Leaders:

Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).

There is a high degree of consolidation in the viral inactivation market, with few large players dominating the market. High degree of consolidation is major barriers for new entrants in this market. Small and medium-sized players account for a small share of the market and their business interests remain concentrated in local markets across emerging geographies.

Rat Model Market Sales, Segments, Capacity Outlook, Growth and Analysis

Major Growth Boosting Factors: The Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. Expanding with the increase in R&D activities in pharmaceutical industries. These rat model are being used in many applications such as toxicology, oncology, diabetes, neurology, immunology and infectious diseases, and others (rare disease, cardiovascular, metabolic disease, hematopoiesis, and regenerative medicines).

Revenue Growth Opportunities: The overall Rat Model Market is expected to reach USD 588.9 million, at a CAGR of 8.7%

Major Market Developments;

# In August 2016, Charles River Laboratories, Inc. entered into a strategic partnership with The Milner Therapeutics Institute and Consortium (UK). This partnership with the Consortium allows the academic institutions access to Charles River’s early discovery and drug development and services for the early stage drug development processes.

# In September, 2016, Charles River Laboratories International, Inc. acquired Agilux Laboratories (US), a provider of bioanalytical services, drug metabolism and pharmacokinetic services, and pharmacology services. This acquisition is expected to compliment Charles River’s non-clinical portfolio and improve the clients’ early-stage research efforts by enabling them to seamlessly transition their drug candidates through the discovery and safety assessment process.

# In October 2015, Horizon Discovery Group plc expanded its UK based headquarters. The new facility is likely to accommodate 200 employees across manufacturing, services, research, and general and administrative functions.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76036494

On the basis of type,

The rat model market is segmented into outbred rats, inbred rats, knockout/genetically engineered rats, hybrid/congenic rats, conditioned/surgically modified rats, and immunodeficient rats model. Knockout/genetically engineered rats segment is expected to grow at the highest CAGR during the forecast period. The high growth rate of knockout/genetically engineered rats segment can be attributed to the use of this type of rat model to carry out researches on disease such as oncology, obesity, heart disease, diabetes, arthritis, drug abuse, anxiety, aging, and Parkinson’s.

On the basis of services,

The rat model market is segmented into breeding, cryopreservation, quarantine, rederivation, model in-licensing, genetic testing, and others such as surgical services, line rescue services, and in vivo pharmacology services. The cryopreservation segment is estimated grow at the highest CAGR during the forecast period, as this segment help in obtaining the genetic material of rats even after the reproductive lifespan of these rats is over. This cuts down time and cost needed for reproduction of rats.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76036494

Applications of Rat Model Market;

DIABETES;

Rats are considered to be excellent experimental models for understanding the complex genetic basis of diseases such as diabetes. Due to the ever-increasing prevalence of diabetes globally; it has become important to study the mechanism of the disease. However, it is quite difficult to carry out research studies in human beings, owing to problems such as genetic heterogeneity and lack of controlled lifestyles. Rat models act as suitable models to study specific genetic mutations and to understand the function of genes on a homogeneous genetic background.

ONCOLOGY;

Rat models recapitulate various aspects of genesis, progression, and clinical course of human cancers. Hence, they act as ideal study models for cancer researchers engaged in a variety of basic, translational, clinical, and epidemiological investigations.

Global Leaders: Charles River Laboratories International, Inc. (U.S.), Taconic Biosciences, Inc. (U.S.), Envigo (U.K.), Laboratory Corporation of America Holdings (U.S.), Biomere (U.S.), Janvier Labs (France), genOway SA (France), and Horizon Discovery Group plc (U.K.) are some of the key players in the rat model market worldwide

COVID-19 Impact on Critical Care Device Market - Segmentation, Major Players & Geographical Analysis

Major Growth Boosting Factors: The Critical Care Device Market is driven primarily by the increasing number of ICU beds owing to the continuously rising COVID-19 cases, increasing demand for ventilators for effective management of critical COVID-19 patients, and ease of regulatory requirements to facilitate the production of critical care devices. In addition, the development of low-cost ventilators and the expected increase in healthcare budgets offer significant growth opportunities for players operating in the critical care devices market. However, disruption of supply chain & logistics due to the rapid spread of coronavirus is likely to challenge the growth of this market.

Revenue Growth Opportunities: The Global COVID-19 Impact on Critical Care Device Market size is expected to reach USD 27.29 billion by 2021 from an estimated value of USD 37.97 billion in 2020. The critical care devices market is expected to witness a growth of 44.1% from 2019 to 2020.

Recent Developments:

• In April 2020, The FDA issued Emergency Use Authorization for B. Braun’s Perfusor Space Syringe Infusion Pump, Infusomat Space Volumetric Infusion Pump, and Outlook ES Pump systems to deliver nebulized meds into a nebulizer to treat COVID-19 patients.
• To help ensure the continuity of supply, BD has placed all BD and Alaris infusion sets on manual inventory allocation until further notice. As a part of the supply continuity plan, the company is also reducing the number of available product SKU’s of Alaris system pump sets.
• In October 2019, B. Braun Medical Inc. (US) collaborated with STANLEY Healthcare (US) to integrate and deploy B. Braun’s Space Infusion Pump Systems along with DoseTrac Infusion Management Software with STANLEY Healthcare’s MobileView software, Aeroscout RTLS MobileView, at Saratoga Hospital, located in New York, US, to provide real-time pump status data.
• In April 2019, Smiths Medical (US) partnered with HCA Capital Division (US) to integrate the Medfusion 4000 system with PharmGuard Software with HCA’s electronic medical records system (EMR), to provide better patient outcomes by reducing medication errors.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=216430576

Based on products;

The critical care devices market is segmented into ventilators & supplies, sleep apnea devices, patient monitors, hyperbaric oxygen therapy devices, infusion pumps, defibrillators, anesthesia machines, blood warmers, and other critical care devices supplies. The ventilators segment is expected to grow at the highest rate during the forecast period. This can be attributed to owing to rapid manufacturing of emergency ventilators, worldwide, and the development of low-cost ventilators.

Based on end-users;

The critical care devices market has been segmented into hospitals, home care settings, ambulatory care settings, and emergency medical services. The hospitals & clinics segment accounted for the largest share of the critical care devices industry in 2019. The large share of this segment is attributed to the strong financial capabilities of hospitals for purchasing high-priced critical care devices, the large patient pool treated at hospitals, and the availability of trained professionals to operate these critical care devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=216430576

Geographical Scenario: The critical care devices market is segmented into five major regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the critical care devices industry. The large share of this region can primarily be attributed to the high adoption of specialty infusion pumps, the high number of positive COVID-19 cases & deaths in the US, a strong healthcare system, and the presence of many large hospitals in the region. Moreover, a large number of major global players are based in the US, owing to which the US can easily manufacture these devices.

Global Leaders: The key players in the global critical care devices market are Becton, Dickinson and Company (US), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Fresenius Kabi (Germany), Medtronic plc (Ireland), ResMed (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare (New Zealand), among others.

COVID-19 impact on Medical Supplies Market - Comprehensive Research Including Top Key Players and Forecast Report

Major Growth Boosting Factors: The market for medical supplies is driven primarily by the growing awareness on environmental & personal hygiene leading to rising demand for disinfectants , expansion of healthcare settings owing to increasing COVID 19 patients, increased requirement of PPE kits & N95 masks globally, rising demand for ventilators, and increasing demand for diagnostic supplies.

In addition, repurposing liquor production lines to manufacture sanitizers offers an opportunity for players in this market. However, delays in non-urgent treatment and surgical procedures and impact on supply chain and logistics due to lockdown is likely to restrain the growth of this market.

Revenue Growth Opportunities: The COVID-19 impact on Medical Supplies Market is expected to reach USD ~100 billion by 2021 from an estimated value of USD ~78 billion in 2019, growing at a CAGR of ~13.4% during the forecast period.

Recent Developments:

• In April 2020, Baxter received USFDA Emergency Use Authorization for Oxiris Blood Purification Filter for COVID-19 Treatment.
• In Arizona, the US, SanTan Brewing, has repurposed its beer production line to manufacture hand sanitizer. In April 2020, SanTan began producing 400 gallons of medical-grade hand sanitizer for first responders and healthcare professionals.
• In New York (US), in March 2020, Pernod Ricard’s facility in Fort Smith, Ark. produced 1,000 gallons of hand sanitizer; it originally produced Malibu coconut rum and Seagram’s gin.
• In India (Bengaluru), Diageo India, which sells McDowell’s whiskey and Smirnoff vodka, announced that it would produce 300,000 liters of hand sanitizers to help overcome the shortage.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=158189339

Based on type,

The medical supplies market is segmented into intubation and ventilation supplies, disinfectant, personal protective equipment, diagnostic supplies, sterilization supplies, infusion and injectable supplies, dialysis supplies, wound care supplies, radiology supplies, and other medical supplies. The disinfectant segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to factors such as the increasing demand for hand sanitizers, rising awareness about personal hygiene, increased consumption of disinfectant in healthcare facilities are driving the growth of the disinfectant market globally.

Based on end users,

The medical supplies market is segmented into hospitals, clinics, and other end-users. The hospital segment is expected to grow at the highest CAGR owing to increasing demand for hospital beds and intensive care units in countries with the increasing incidence of COVID-19, increasing demand for specialized staff such as infectious disease experts providers, respiratory therapists, and physicians and nurses who can provide intensive and critical care, increased consumption of personnel protective equipment within the hospital premises; and the increasing support from government and non-government organization to combat with COVID-19 are the major factors driving the demand and uptake of medical supplies in hospitals growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158189339

Geographical Scenario:

North America accounted for the largest share of the medical supplies market in 2020, followed by Europe. The large share of this region is attributed mainly to a high number of positive COVID-19 cases and deaths in the US, a strong healthcare system, and the presence of many large hospitals. Moreover, a large number of major global players are based in the US, owing to which the US can easily manufacture these devices.

Global Leaders:

The prominent players in the medical supplies market are Medtronic plc (Ireland), Cardinal Health, Inc. (US), Becton, Dickson and Company (US), Johnson & Johnson (US), and B. Braun Melsungen AG (Germany), Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), STERIS Corporation (US), Getinge Group (Sweden), Advanced Sterilization Products (US), 3M Company (US), Smith & Nephew (U.K.), Mölnlycke Health Care AB (Sweden),  among others.